Cadrenal Therapeutics Inc (CVKD) - מקדם חוב לטווח ארוך להון

The long-term debt-to-equity ratio for Cadrenal Therapeutics (CVKD) demonstrates the impact of geopolitical risks on raw material logistics, with the metric holding around 0.00. Leverage stability is supported by management's focus on nephrology innovations. However, the absence of current sales and the dependence of capitalization on anticoagulant test results make the financial structure sensitive to any regulatory changes.

This metric reflects the balance sheet's sensitivity to long-term financing relative to equity. It measures the proportion of loans with maturities exceeding one year, determining the issuer's pace of financial recovery. For Cadrenal Therapeutics (CVKD), this calculation is critical due to costly clinical trials and the patent protection of formulas. An analysis of the long-term debt-to-equity ratio reveals the balance between leveraged capital and investment potential.